Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.200
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
2.220
+0.020 (0.91%)
After-hours: Dec 5, 2025, 7:55 PM EST
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $67.46M in the quarter ending September 30, 2025, with 15.20% growth. This brings the company's revenue in the last twelve months to $250.43M, up 175.62% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$250.43M
Revenue Growth
+175.62%
P/S Ratio
2.91
Revenue / Employee
$298,837
Employees
838
Market Cap
873.33M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IOVA News
- 15 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode - Seeking Alpha
- 25 days ago - Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? - The Motley Fool
- 4 weeks ago - 2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - The Motley Fool
- 4 weeks ago - Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders - GlobeNewsWire
- 7 weeks ago - Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health - The Motley Fool
- 7 weeks ago - Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? - The Motley Fool